These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 16925790

  • 1. Effect of repeated apotransferrin administrations on serum iron parameters in patients undergoing myeloablative conditioning and allogeneic stem cell transplantation.
    Parkkinen J, Sahlstedt L, von Bonsdorff L, Salo H, Ebeling F, Ruutu T.
    Br J Haematol; 2006 Oct; 135(2):228-34. PubMed ID: 16925790
    [Abstract] [Full Text] [Related]

  • 2. Effective binding of free iron by a single intravenous dose of human apotransferrin in haematological stem cell transplant patients.
    Sahlstedt L, von Bonsdorff L, Ebeling F, Ruutu T, Parkkinen J.
    Br J Haematol; 2002 Nov; 119(2):547-53. PubMed ID: 12406099
    [Abstract] [Full Text] [Related]

  • 3. Non-transferrin-bound iron in haematological patients during chemotherapy and conditioning for autologous stem cell transplantation.
    Sahlstedt L, von Bonsdorff L, Ebeling F, Parkkinen J, Juvonen E, Ruutu T.
    Eur J Haematol; 2009 Nov; 83(5):455-9. PubMed ID: 19572995
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Fluorescence assay of non-transferrin-bound iron in thalassemic sera using bacterial siderophore.
    Sharma M, Saxena R, Gohil NK.
    Anal Biochem; 2009 Nov 15; 394(2):186-91. PubMed ID: 19632191
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The relationship between transferrin saturation and erythropoiesis during stem cell transplantation.
    Altes A, Remacha AF, Sarda P, Baiget M, Canals C, Sierra J.
    Haematologica; 2006 Jul 15; 91(7):992-3. PubMed ID: 16818289
    [Abstract] [Full Text] [Related]

  • 9. A fluorescence-based one-step assay for serum non-transferrin-bound iron.
    Breuer W, Cabantchik ZI.
    Anal Biochem; 2001 Dec 15; 299(2):194-202. PubMed ID: 11730343
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Impact of non-transferrin-bound iron (NTBI) in comparison to serum ferritin on outcome after allogeneic stem cell transplantation (ASCT).
    Hilken A, Langebrake C, Wolschke C, Kersten JF, Rohde H, Nielsen P, Kröger N.
    Ann Hematol; 2017 Aug 15; 96(8):1379-1388. PubMed ID: 28585071
    [Abstract] [Full Text] [Related]

  • 13. Non-transferrin-bound iron during allogeneic stem cell transplantation.
    Sahlstedt L, Ebeling F, von Bonsdorff L, Parkkinen J, Ruutu T.
    Br J Haematol; 2001 Jun 15; 113(3):836-8. PubMed ID: 11380478
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF, Fan ZP, Zhang Y, Jiang ZJ, Wang CY, Xu D, Sun J, Xiao Y, Tan H.
    Biol Blood Marrow Transplant; 2009 Nov 15; 15(11):1376-85. PubMed ID: 19822296
    [Abstract] [Full Text] [Related]

  • 16. Non-transferrin-bound iron during blood transfusion cycles in beta-thalassemia major.
    Grosse R, Lund U, Caruso V, Fischer R, Janka GE, Magnano C, Engelhardt R, Dürken M, Nielsen P.
    Ann N Y Acad Sci; 2005 Nov 15; 1054():429-32. PubMed ID: 16339692
    [Abstract] [Full Text] [Related]

  • 17. Residual erythropoiesis protects against myocardial hemosiderosis in transfusion-dependent thalassemia by lowering labile plasma iron via transient generation of apotransferrin.
    Garbowski MW, Evans P, Vlachodimitropoulou E, Hider R, Porter JB.
    Haematologica; 2017 Oct 15; 102(10):1640-1649. PubMed ID: 28642302
    [Abstract] [Full Text] [Related]

  • 18. Development of a pharmaceutical apotransferrin product for iron binding therapy.
    von Bonsdorff L, Tölö H, Lindeberg E, Nyman T, Harju A, Parkkinen J.
    Biologicals; 2001 Mar 15; 29(1):27-37. PubMed ID: 11482890
    [Abstract] [Full Text] [Related]

  • 19. Exogenous apotransferrin and exchange transfusions in hereditary iron overload disease.
    Fellman V, von Bonsdorff L, Parkkinen J.
    Pediatrics; 2000 Feb 15; 105(2):398-401. PubMed ID: 10654962
    [Abstract] [Full Text] [Related]

  • 20. Common presence of non-transferrin-bound iron among patients with type 2 diabetes.
    Lee DH, Liu DY, Jacobs DR, Shin HR, Song K, Lee IK, Kim B, Hider RC.
    Diabetes Care; 2006 May 15; 29(5):1090-5. PubMed ID: 16644642
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.